NetworkNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands European Clinical Network to Support GelrinC(R) Commercial Strategy
Regentis Biomaterials (NYSE American: RGNT) announced the expansion of its European clinical site network into new markets, including Italy and Eastern Europe, to support ongoing clinical programs and the commercial strategy for GelrinC(R), which has received CE Mark approval for knee cartilage repair. The expanded network includes leading academic and regional medical centers across Italy, Germany, Serbia, Slovenia and Romania, strengthening the company’s engagement with orthopedic surgeons and centers of excellence as it advances broader clinical adoption and evaluates commercial partnership opportunities in Europe. To view the full press release, visit https://nnw.fm/ala7S About Regentis Biomaterials Regentis Biomaterials Ltd is a…







